Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science (RC2 Clinical Trials Optional)

US National Institutes of Health (NIH) grant open #PAR-25-156

Response due Sep 28, 2026 · 00:00 UTC

Summary

This is a limited competition federal grant opportunity issued by the National Institutes of Health (NIH) under program announcement PAR-25-156. It solicits high-impact, specialized innovation programs in the domain of clinical and translational science. The RC2 mechanism indicates it is a high-priority, time-sensitive research award. Clinical trials are optional under this funding opportunity. The competition is restricted, meaning not all applicants are eligible — only those meeting specific pre-qualification criteria set by NIH.

What they want

Technical requirements

Clinical trials component is optional (not required)
Must align with RC2 grant mechanism requirements
Must address high-impact specialized innovation in clinical and translational science

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

Limited competition designation restricts eligible applicants — RFP may be structured to favor a narrow set of pre-qualified institutions
No dollar values or award size disclosed in the opportunity text
Multi-year open window (Dec 2024 – Sep 2026) is unusual and may reflect rolling invitations to specific awardees

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Limited Competition: High Impact Specializ…

Due Sep 28

Onboard ↗